Please login to the form below

Not currently logged in
Email:
Password:

BMS to buy Amira Pharmaceuticals

Bristol-Myers Squibb is to purchase inflammatory and fibrotic disease specialists Amira Pharmaceuticals in an acquisition potentially worth $475m

Bristol-Myers Squibb (BMS) is to purchase inflammatory and fibrotic disease specialists Amira Pharmaceuticals in an acquisition potentially worth $475m.

California-based Amira will receive $325m in upfront payments, with additional milestones totalling $150m.

Once the deal is complete, BMS will have access to Amira's fibrosis programme, including the investigative drug AM152, which is about to enter phase II clinical development.

Amira also has a preclinical programme for autotoxin – an enzyme associated with tumours.

BMS said it will retain Amira's scientists working on these projects.

Elliott Sigal, executive vice president, chief scientific officer and president, Research and Development at BMS, described fibrotic diseases as an area of "high unmet medical need." The Amira acquisition part of the company's plans to diversify its pipeline, he added.

25th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics